Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vaxcyte, Inc.

36.99
+2.196.29%
Pre-market: 36.95-0.0400-0.11%05:28 EDT
Volume:1.58M
Turnover:57.97M
Market Cap:4.77B
PE:-9.29
High:37.11
Open:35.06
Low:35.02
Close:34.80
Loading ...

Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Vaxcyte (PCVX) and Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
23 May

Bank of America Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)

TIPRANKS
·
14 May

Stock Track | Vaxcyte (PCVX) Soars 5.14% Following Needham Analyst's Buy Rating

Stock Track
·
08 May

Vaxcyte’s Long-Term Potential Overshadows Market Challenges: A Buy Recommendation

TIPRANKS
·
08 May

Optimistic Outlook for Vaxcyte’s Vaccines Drives Buy Rating

TIPRANKS
·
08 May

Vaxcyte Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Vaxcyte Q1 EPS $(1.04) Beats $(1.11) Estimate

Benzinga
·
08 May

BRIEF-Vaxcyte Q1 Cash & Investments USD 2,950.762 Million

Reuters
·
08 May

Vaxcyte Inc. Reports Q1 2025 Net Loss of $140.7 Million, Up from $95 Million in Q1 2024

Reuters
·
08 May

Vaxcyte Q1 Cash & Investments USD 2,950.762 Million

THOMSON REUTERS
·
08 May

Vaxcyte Inc - Holds $3 Billion in Cash, Cash Equivalents and Investments as of March 2025

THOMSON REUTERS
·
08 May

Vaxcyte Inc: Qtrly Loss per Share $1.04

THOMSON REUTERS
·
08 May

Vaxcyte Appoints DR. Olivier Brandicourt to Board of Directors

THOMSON REUTERS
·
01 May

Press Release: Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Dow Jones
·
01 May

Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom -- Barrons.com

Dow Jones
·
22 Apr

Vaxcyte Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
22 Apr

Vaxcyte initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
22 Apr

Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller’s Top Stock Pick with Huge Upside Potential

Insider Monkey
·
12 Apr

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Zacks
·
11 Apr

Vaxcyte Price Target Maintained With a $90.00/Share by Needham

Dow Jones
·
08 Apr